Visipaque™ (Iodixanol) Injection

Visipaque™ (iodixanol) injection - the only contrast media for intravascular use that is iso-osmolar to blood and isotonic at all concentrations in the US
Support
AT A GLANCE

25+ years of clinical use

May help mitigate risk of MARCE in comorbid patients1

Improved patient care

Iso-osmolar to blood to minimize vascular fluid shift

Isotonic to blood

Minimizing impact of differences in osmotic pressure

Helps reduce costs

Lower hospitalization costs due to shortened length of stay2

Visipaque: Prepared for high risk patients

More than 1 in 7 adults in the US are estimated to have CKD, and most don't know it.3 34.2 million Americans - just over 1 in 10 - have diabetes.4 By 2060, 1 in 4 people in the US will be aged 65+, with the number over 85 years expected to nearly triple.5

Appropriate selection of contrast media for necessary diagnostic or interventional procedure imaging in high risk patients should be considered to help mitigate the risk of adverse events.6 Visipaque, an iodinated iso-osmolar, isotonic contrast agent indicated for multiple intra-arterial and intravenous procedures, was prepared with this in mind.
FEATURES

Your choice of iodinated contrast media could help mitigate adverse events

Interventional, structural, or endovascular procedures (e.g., TAVI, CTO, PCI) may need to use higher volumes of iodinated CM. Reducing the frequency of adverse reactions has therefore been a driving force in the development of these diagnostic agents since their initial introduction.6,7
SAFETY

High risk patient populations are ever growing8,9

Visipaque is a third-generation agent with a unique molecular structure developed to further improve the safety profile of iodinated contrast agents.8,10 It is iso-osmolar to blood with the aim of counteracting major fluid shifts across membranes and limiting discomfort.10,11 It is also formulated with balanced electrolytes to help minimize effects on cardiac contractile force/fibrillatory propensity.10,11 While 'low' osmolar agents form the mainstay in the general population of patients undergoing endovascular diagnostic or interventional procedures, Visipaque may be preferred for more complex procedures in patients considered at high risk for cardiovascular or renal insult.1,8
PACKAGING

Get your job done easier and faster with improved packaging

Introducing the flip top cap on our +PLUSPAK™ polymer bottles. This packaging facilitates opening the cap and is an improvement on the ring pull design. This new design helps reduce costs and environmental impact with less storage space needed and lower disposal costs.12-14 It helps to streamline processes and traceability through color coding, triple-tracking stickers, a 2D DataMatrix, and an integrated hanger with a label easy to read even when inverted.
VALUE

Can help reduce cost by helping to reduce risk

When compared to total interventional procedure cost, contrast media is inexpensive but CA-AKI and contrast media-related adverse events may increase the use of health care resources and cost of care.15 Given the growth of vulnerable patient populations, practices that reduce CA-AKI incidence and its associated costs are important to identify.2

According to a study conducted to determine the net economic impact of switching from low-osmolar contrast media (LOCM) to iso-osmolar contrast media (IOCM; iodixanol) in patients undergoing inpatient coronary or peripheral angioplasty in the US, moving on to an IOCM-only strategy may yield substantial cost savings to US hospitals where coronary and peripheral procedures are performed.2
EVIDENCE-BASED

Data you can trust for interventional cardiology

Randomized controlled trials often do not address all the clinical scenarios that confront physicians.16,17 Specifically in interventional cardiology, high-risk patients are often routinely excluded from revascularization randomized controlled trials (RCTs).18,19 Real-world data complement traditional clinical trials, with broader populations and health care delivery that reflects actual clinical practice.20

In the interventional cardiology setting, use of iso-osmolar Visipaque is supported by:
• Robust randomized controlled trials21-24
• Meta-analyses of intra-arterial studies25-27
• Real-world data from the cath-lab28
REDUCE PATIENT DISCOMFORT

Increased patient comfort can help improve throughput

Enhancing interventional radiology procedural comfort is important for both patients and efficiency, as movement may necessitate studies being repeated or prolonged.29-31

A benefit of iso-osmolar Visipaque is the reduction in pain associated in arteriography.32 According to the ACR, iso-osmolar CM “...are associated with the least amount of vasospasm and the least peripheral discomfort for peripheral angiograms”.33

Support you need for your procedures

Learn more about supporting resources available for Visipaque.

Educational programs

Contrast-associated acute kidney injury (CA-AKI) is a challenge that may be encountered in the cardiac catheterization lab.

REFERENCES
  1. Ronco F, Tarantini G, McCullough PA. Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians. Rev Cardiovasc Med. 2020; 21:9-23.
  2. Keuffel E et al. J Med Econ. 2018;21:356-364.
  3. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2021.
  4. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020.
  5. Vespa, Jonathan, Lauren Medina, and David M. Armstrong, “Demographic Turning Points for the United States: Population Projections for 2020 to 2060,” Current Population Reports, P25-1144, U.S. Census Bureau, Washington, DC, 2020.
  6. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380(22):2146-2155.
  7. Christiansen C. X-ray contrast media-an overview. Toxicology. 2005; 209(2): 185-7.
  8. Widmark JM. Imaging-related medications: a class overview. Proc (Bayl Univ Med Cent). 2007; 20(4): 408-17.
  9. Keuffel E, McCullough PA, Todoran TM, et al. J Med Econ. 2017; 21(4): 356-64.x
  10. Almén T. Visipaque – a step forward a historical review Acta Radiol. 1995; 36(Suppl.399): 2-18.x
  11. Fountaine H, Harnish P, Andrew E, Grynne B. Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, isosmolar, hexa-iodinated contrast agent. Acad Radiol. 1996; 3 Suppl 3:S475-84.
  12. Marshall G. Sharps injuries among radiographers: Dangers associated with opening bottles of contrast agent. Radiography. 2008;14:128-134.
  13. Gricar J, Deutsch S, Blackburn J, Zyczynski T. The economic and safety impact of glass versus polymer containers in a radiology department. Radiol Manage. 2007;Sep/Oct:34-42.
  14. Dhaliwal H, Browne M, Flanagan W, Laurin L, Hamilton M. A life cycle assessment of packaging options for contrast media delivery: comparing polymer bottle vs. glass bottle. Int J Life Cycle Assess. 2014;19:1965-1973.
  15. Aspelin P et al. Am Heart J. 2005;149(2):298-303.
  16. Kerneis M, Nafee T, et al. Most promising therapies in interventional cardiology. Curr Cardiol Rep. 2019; 21(4): 26.
  17. Bonow RO, Braunwald E. The evidence supporting cardiovascular guidelines – Is there evidence of progress in the last decade? JAMA. 2019; 321(11): 1053-4.
  18. De Marzo V, D’Amario D, Galli M, Vergallo R, Porto I. High-risk percutaneous coronary intervention: how to define it today? Minerva Cardioangiol. 2018; 66(5): 576-93.
  19. Kinnaird T, Gallagher S, et al. Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome? Am Heart J. 2020; 222: 15-25.
  20. Sherman RE, Anderson SA, et al. Real-world evidence – What is it and what can it tell us? N Engl J Med. 2016; 375: 2293-7.
  21. Aspelin P, Aubry P, Fransson S-G, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348(6): 491-9.
  22. Harrison JK, Hermiller JB, et al. A randomized study of 1276 patients undergoing PCI using iodixanol (Visipaque) vs iopamidol (Isovue); comparison of in-hospital and 30 day major adverse cardiac event. The results of the VICC trial. Am Heart J. 2004; 147(4): 612-14.
  23. Davidson CJ, Laskey WK, et al. Randomized trial of contrast media utilization in high-risk PTCA. The COURT trial. Circulation. 2000; 101(18): 2172-7.
  24. Nie B, Cheng W-J, et al. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Catheter Cardiovasc Interv. 2008; 72(7):958-65.
  25. McCullough PA, Brown JR. Effects of intra-arterial and intravenous iso-osmolar contrast medium (iodixanol) on the risk of contrast-induced acute kidney injury: a meta-analysis. Cardiorenal Med. 2011; 1(4): 220-24.
  26. Dong M, Jiao Z, Liu T, Guo F, Li G. Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials. J Nephrol. 2012; 25(3): 290-301.
  27. Zhao F, Lei R, et al. Comparative effect of iso-osmolar versus low-osmolar contrast media on the incidence of contrast-induced acute kidney injury in diabetic patients: a systematic review and meta-analysis. Cancer Imaging. 2019; 19(1): 38.
  28. McCullough PA, David G, Todoran TM, Brilakis ES, Ryan MP, Gunnarsson C. Iso-osmolar contrast media and adverse renal and cardiac events after percutaneous cardiovascular intervention. J Comp Eff Res. 2017; 7(4): 331-41.
  29. RCR. Clinical radiology. UK workforce census 2018 report. London: RCR, April 2019.
  30. Ortiz-Lopez C, Prasad A. Iso-osmolar contrast (iodixanol) reduces patient and operator pain during peripheral angiography. Catheter Cardiovasc Interv. 2014; 84(6): 1026-7.
  31. Palena LM, Sacco ZD, et al. Discomfort assessment in peripheral angiography: randomized clinical trial of iodixanol 270 versus ioversol 320 in diabetics with critical limb ischemia. Catheter Cardiovasc lnterv. 2014; 84(6): 1019-25.
  32. Almén T. Visipaque – a step forward a historical review Acta Radiol. 1995; 36(Suppl.399): 2-18.
  33. ACR Manual on Contrast Media. Version 10.3. 2020.

Have a question? We would love to hear from you.

Contact us

IMPORTANT SAFETY INFORMATION FOR VISIPAQUE (iodixanol) INJECTION

 WARNING: NOT FOR INTRATHECAL USE
Inadvertent intrathecal administration may cause death, convulsions/seizures,
cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest,
rhabdomyolysis, hyperthermia, and brain edema.

CONTRAINDICATION: Visipaque injection is contraindicated for intrathecal use.

WARNINGS AND PRECAUTIONS:
• Hypersensitivity Reactions: Life-threatening or fatal reactions can occur. Most severe reactions develop shortly after the start of the injection, but reactions can occur up to hours later. Always have emergency equipment and trained personnel available.
• Contrast Induced Acute Kidney Injury: Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk.
• Cardiovascular Reactions: Life-threatening or fatal cardiovascular reactions, including hypotension, shock, and cardiac arrest have occurred with the use of Visipaque. Most deaths occur during injection or five to ten minutes later, with cardiovascular disease as the main aggravating factor. Use the lowest necessary dose of Visipaque in patients with congestive heart failure.
• Thromboembolic Events: Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiocardiography procedures with both ionic and nonionic contrast agents.
• Extravasation and Injection Site Reactions: Extravasation of Visipaque injection may cause tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease. Ensure intravascular placement of catheters prior to injection.
• Thyroid Storm in Patients With Hyperthyroidism: Thyroid storm has occurred after the intravascular use of iodinated contrast agents in patients with hyperthyroidism, or with an autonomously functioning thyroid nodule.
• Hypertensive Crisis in Patients With Pheochromocytoma: Hypertensive crisis has occurred after the use of iodinated contrast agents in patients with pheochromocytoma. Inject the minimum amount of contrast necessary, assess the blood pressure throughout the procedure, and have measures for treatment of a hypertensive crisis readily available.
• Sickle Cell Crisis in Patients With Sickle Cell Disease: Iodinated contrast agents when administered intravascularly may promote sickling in individuals who are homozygous for sickle cell disease.
• Severe Cutaneous Adverse Reactions: Severe cutaneous adverse reactions (SCARs) may develop from one hour to several weeks after intravascular contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS). Avoid administering Visipaque to patients with a history of a SCAR to Visipaque.
• Pediatric Use: Pediatric patients at high risk of adverse reactions during and after administration of contrast agents include those with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, chronic heart failure, or a serum creatinine >1.5 mg/dL. Patients with immature renal function or dehydration may be at increased risk due to prolonged elimination of iodinated contrast agents. Thyroid dysfunction in pediatric patients 0 to 3 Years of Age: Monitor these patients for thyroid function abnormalities and treat as clinically needed.
• Geriatric Use: While no overall differences in safety or effectiveness were observed in patients >65 years, greater sensitivity regarding some older individuals cannot be ruled out.

ADVERSE REACTIONS:
• Serious, life-threatening, and fatal reactions, mostly of cardiovascular origin, have been associated with the administration of iodine-containing contrast agents, including Visipaque Injection. 
• Most common adverse reactions (incidence greater than 0.5%) in adult patients after Visipaque injection: Discomfort, warmth, pain; Cardiovascular: angina. Gastrointestinal: diarrhea, nausea, vomiting. Nervous System: agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning. Skin: itchy rash, severe itching, hives. Special Senses: Smell, taste, and vision alteration. Pediatric patients experienced similar adverse reactions.

Please see the full Prescribing Information, including Boxed Warning for additional important safety information.
 
To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800 654 0118 (option 2, then option 1), or the FDA at 800 FDA 1088 or www.fda.gov/medwatch.

 

Product Indications

Intra-Arterial Procedures
Adult and pediatric patients 12 years of age and older: Intra-arterial digital subtraction angiography (270 and 320 mg iodine/mL); angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg iodine/mL). Pediatric patients less than 12 years of age: Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg iodine/mL)

Intravenous Procedures
Adult and pediatric patients 12 years of age and older: Computed tomography (CT) imaging of the head and body (270 and 320 mg iodine/mL); excretory urography (270 and 320 mg iodine/mL); peripheral venography (270 mg iodine/mL); coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of patients with suspected  artery disease (320 mg iodine/mL). Pediatric patients less than 12 years of age: CT imaging of the head and body (270 mg iodine/mL); excretory urography (270 mgiodine/mL)

Please see full Prescribing Information for Visipaque and full Prescribing Information for Visipaque Bulk Package.

JB07513US July 2024